智通财经APP讯,和铂医药-B(02142)公布,用于治疗特应性皮炎的靶向胸腺基质淋巴细胞生成素(TSLP)及一个未公开靶点的长效双特异性抗体HBM7575(亦称 SKB575)的新药临床试验(IND)申请已获中国国家药品监督管理局(NMPA)批准。
智通财经APP讯,和铂医药-B(02142)公布,用于治疗特应性皮炎的靶向胸腺基质淋巴细胞生成素(TSLP)及一个未公开靶点的长效双特异性抗体HBM7575(亦称 SKB575)的新药临床试验(IND)申请已获中国国家药品监督管理局(NMPA)批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.